REVOLUTION MEDICINES INC (RVMD) Fundamental Analysis & Valuation

NASDAQ:RVMD • US76155X1000

98.4 USD
-1.24 (-1.24%)
At close: Mar 6, 2026
98.385 USD
-0.02 (-0.02%)
After Hours: 3/6/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This RVMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

RVMD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. RVMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RVMD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. RVMD Profitability Analysis

1.1 Basic Checks

  • RVMD had negative earnings in the past year.
  • RVMD had a negative operating cash flow in the past year.
  • RVMD had negative earnings in each of the past 5 years.
  • RVMD had a negative operating cash flow in each of the past 5 years.
RVMD Yearly Net Income VS EBIT VS OCF VS FCFRVMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M -800M -1B

1.2 Ratios

  • With a Return On Assets value of -48.05%, RVMD perfoms like the industry average, outperforming 51.35% of the companies in the same industry.
  • RVMD has a Return On Equity of -69.35%. This is comparable to the rest of the industry: RVMD outperforms 55.58% of its industry peers.
Industry RankSector Rank
ROA -48.05%
ROE -69.35%
ROIC N/A
ROA(3y)-30.89%
ROA(5y)-29.73%
ROE(3y)-39.91%
ROE(5y)-37.42%
ROIC(3y)N/A
ROIC(5y)N/A
RVMD Yearly ROA, ROE, ROICRVMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RVMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RVMD Yearly Profit, Operating, Gross MarginsRVMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. RVMD Health Analysis

2.1 Basic Checks

  • RVMD has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, RVMD has more shares outstanding
  • Compared to 1 year ago, RVMD has a worse debt to assets ratio.
RVMD Yearly Shares OutstandingRVMD Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
RVMD Yearly Total Debt VS Total AssetsRVMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • RVMD has an Altman-Z score of 13.93. This indicates that RVMD is financially healthy and has little risk of bankruptcy at the moment.
  • RVMD's Altman-Z score of 13.93 is amongst the best of the industry. RVMD outperforms 85.96% of its industry peers.
  • A Debt/Equity ratio of 0.16 indicates that RVMD is not too dependend on debt financing.
  • RVMD's Debt to Equity ratio of 0.16 is on the low side compared to the rest of the industry. RVMD is outperformed by 64.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 13.93
ROIC/WACCN/A
WACCN/A
RVMD Yearly LT Debt VS Equity VS FCFRVMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B

2.3 Liquidity

  • A Current Ratio of 7.14 indicates that RVMD has no problem at all paying its short term obligations.
  • RVMD has a Current ratio of 7.14. This is in the better half of the industry: RVMD outperforms 70.19% of its industry peers.
  • RVMD has a Quick Ratio of 7.14. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
  • RVMD has a Quick ratio of 7.14. This is in the better half of the industry: RVMD outperforms 70.19% of its industry peers.
Industry RankSector Rank
Current Ratio 7.14
Quick Ratio 7.14
RVMD Yearly Current Assets VS Current LiabilitesRVMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. RVMD Growth Analysis

3.1 Past

  • RVMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -65.55%.
EPS 1Y (TTM)-65.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • RVMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.93% yearly.
  • The Revenue is expected to grow by 284.00% on average over the next years. This is a very strong growth
EPS Next Y-26.4%
EPS Next 2Y-4.68%
EPS Next 3Y4.8%
EPS Next 5Y24.93%
Revenue Next Year966.48%
Revenue Next 2Y669.24%
Revenue Next 3Y435.27%
Revenue Next 5Y284%

3.3 Evolution

RVMD Yearly Revenue VS EstimatesRVMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B 8B
RVMD Yearly EPS VS EstimatesRVMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

0

4. RVMD Valuation Analysis

4.1 Price/Earnings Ratio

  • RVMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVMD Price Earnings VS Forward Price EarningsRVMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVMD Per share dataRVMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.68%
EPS Next 3Y4.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RVMD Dividend Analysis

5.1 Amount

  • No dividends for RVMD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RVMD Fundamentals: All Metrics, Ratios and Statistics

REVOLUTION MEDICINES INC

NASDAQ:RVMD (3/6/2026, 8:00:02 PM)

After market: 98.385 -0.02 (-0.02%)

98.4

-1.24 (-1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners100.45%
Inst Owner Change-2.75%
Ins Owners1.85%
Ins Owner Change-1.89%
Market Cap19.50B
Revenue(TTM)N/A
Net Income(TTM)-1.13B
Analysts87.41
Price Target124.38 (26.4%)
Short Float %7.17%
Short Ratio3.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.3%
Min EPS beat(2)-15.36%
Max EPS beat(2)-11.24%
EPS beat(4)0
Avg EPS beat(4)-10.23%
Min EPS beat(4)-15.36%
Max EPS beat(4)-1.54%
EPS beat(8)1
Avg EPS beat(8)-6.23%
EPS beat(12)3
Avg EPS beat(12)-5.8%
EPS beat(16)6
Avg EPS beat(16)-2.46%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)34%
PT rev (3m)53.03%
EPS NQ rev (1m)0.23%
EPS NQ rev (3m)1.73%
EPS NY rev (1m)0.01%
EPS NY rev (3m)-4.36%
Revenue NQ rev (1m)6.24%
Revenue NQ rev (3m)34.31%
Revenue NY rev (1m)6.68%
Revenue NY rev (3m)13.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.95
P/tB 12.49
EV/EBITDA N/A
EPS(TTM)-5.91
EYN/A
EPS(NY)-7.47
Fwd EYN/A
FCF(TTM)-4.61
FCFYN/A
OCF(TTM)-4.53
OCFYN/A
SpS0
BVpS8.23
TBVpS7.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.05%
ROE -69.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.89%
ROA(5y)-29.73%
ROE(3y)-39.91%
ROE(5y)-37.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 184.86%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.14
Quick Ratio 7.14
Altman-Z 13.93
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)148.83%
Cap/Depr(5y)163.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-65.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.07%
EPS Next Y-26.4%
EPS Next 2Y-4.68%
EPS Next 3Y4.8%
EPS Next 5Y24.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year966.48%
Revenue Next 2Y669.24%
Revenue Next 3Y435.27%
Revenue Next 5Y284%
EBIT growth 1Y-71.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.29%
EBIT Next 3Y2.44%
EBIT Next 5Y23.57%
FCF growth 1Y-60.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.05%
OCF growth 3YN/A
OCF growth 5YN/A

REVOLUTION MEDICINES INC / RVMD FAQ

What is the ChartMill fundamental rating of REVOLUTION MEDICINES INC (RVMD) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RVMD.


What is the valuation status for RVMD stock?

ChartMill assigns a valuation rating of 0 / 10 to REVOLUTION MEDICINES INC (RVMD). This can be considered as Overvalued.


How profitable is REVOLUTION MEDICINES INC (RVMD) stock?

REVOLUTION MEDICINES INC (RVMD) has a profitability rating of 1 / 10.


How financially healthy is REVOLUTION MEDICINES INC?

The financial health rating of REVOLUTION MEDICINES INC (RVMD) is 5 / 10.


What is the expected EPS growth for REVOLUTION MEDICINES INC (RVMD) stock?

The Earnings per Share (EPS) of REVOLUTION MEDICINES INC (RVMD) is expected to decline by -26.4% in the next year.